Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies

NCT06564038 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06564038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06564038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 30, 2025
Completion date
June 11, 2029
Enrollment
408 (estimated)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin lymphoma, chronic lymphocytic leukaemia, large b-cell lymphoma, mantle-cell lymphoma, small lymphocytic lymphoma